Mydriasert (Phenylephrine Hydrochloride, Tropicamide)

Phenylephrine Hydrochloride and Tropicamide, the active ingredients in Mydriasert, are mydriatic agents presented as an ophthalmic solution for ocular use. They work together to dilate the pupil and temporarily paralyze accommodation, facilitating detailed eye examinations and surgical procedures. GNH USA supplies Mydriasert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mydriasert, a combination mydriatic eye drop, is used in ophthalmic settings where pupil dilation is required. - Pharmacologic pupil dilation for ophthalmic examinations: provides adequate dilation for detailed retinal evaluation. - Facilitation of intra‑ocular surgery: enables sufficient pupil enlargement for surgical access. - Diagnostic mydriasis: supports diagnostic procedures that require a clear view of intra‑ocular structures.

Mydriasert may cause ocular and systemic reactions after administration.

Common Side Effects: - Transient ocular discomfort or stinging sensation. - Blurred vision lasting several hours. - Photophobia due to enlarged pupil. - Mild conjunctival hyperemia. - Temporary increase in intra‑ocular pressure.

Serious or Rare Side Effects: - Acute angle‑closure glaucoma. - Severe allergic reaction (e.g., angio‑edema, anaphylaxis). - Corneal edema. - Systemic hypertension or tachycardia. - Ocular ischemia or retinal vascular events.

Before using Mydriasert, consider the following safety measures. - Assess baseline intra‑ocular pressure: measure IOP prior to administration. - Avoid use in patients with narrow‑angle glaucoma: contraindicated due to risk of angle‑closure. - Use with caution in patients with cardiovascular disease: monitor blood pressure and heart rate. - Do not combine with other mydriatic agents unless directed by a clinician. - Store at room temperature: keep in the original container, protect from light and moisture.

Mydriasert can interact with systemic and ocular medications.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): may precipitate hypertensive crisis. - Systemic sympathomimetics (e.g., epinephrine): additive cardiovascular stimulation.

Moderate Interactions (Monitor Closely):\n- Other ocular mydriatics: may cause excessive pupil dilation. - Anticholinergic drugs: increased cycloplegic effect. - Topical corticosteroids: potential for elevated intra‑ocular pressure.